Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,000 shares of Vor Bio's common stock and restricted stock units ("RSUs") representing the right to receive an aggregate of 1,500 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the "Inducement Plan").
美國馬薩諸塞州劍橋市，2024年6月4日/環球新聞線/ -- Vor Bio (納斯達克股票代碼：VOR)是一家臨床階段的細胞和基因工程公司，今天宣佈，自2024年6月1日起，董事會補償委員會向一名新員工授予了購買1,000股Vor Bio普通股和代表有權收到1,500股Vor Bio普通股的限制性股票單位（“RSUs”）的股票期權。上述股票期權和限制性股票單位是根據納斯達克上市規則5635(c)(4)條款在2023年Vor Biopharma公司 誘因計劃（“誘因計劃”）下授予的。
The stock options have a ten-year term and an exercise price of $1.41 per share, which is equal to the closing price of Vor Bio's common stock on June 3, 2024. The options will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee's continued employment with Vor Bio on such vesting dates. The RSUs will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting quarterly over the following 36 months, subject to the employee's continued employment with Vor Bio on such vesting dates. The options and RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an award agreement covering the grants.
這些股票期權的期限爲十年，行使價格爲每股1.41美元，這與2024年6月3日維爾生物普通股的收盤價格相等。這些期權將在四年內按比例解除限制，其中25％的股份將在12個月後解除限制，其餘股份將在隨後的36個月內每月按比例解除限制，前提是員工在這些限制解除日期繼續在維爾生物工作。RSU將在四年內按比例解除限制，其中25％的股份將在12個月後解除限制，其餘股份將在隨後的36個月內每季度按比例解除限制，前提是員工在這些限制解除日期繼續在維爾生物工作。期權和RSU受激勵計劃條款和授予獎勵的獎勵協議條款的約束。
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
關於維爾生物
Vor Bio是一家臨床階段的細胞和基因工程公司，旨在通過工程造血幹細胞以實現移植後的定向治療，改變血液癌症患者的治療標準。更多信息請訪問：www.vorbio.com.
Contact:
Investors & Media
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
聯繫方式：
投資者和媒體
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
譯文內容由第三人軟體翻譯。